NASDAQ:ATOS Atossa Genetics Q1 2025 Earnings Report $4.96 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.82 -0.14 (-2.90%) As of 05/22/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Atossa Genetics EPS ResultsActual EPS-$0.75Consensus EPS -$0.90Beat/MissBeat by +$0.15One Year Ago EPSN/AAtossa Genetics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAtossa Genetics Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateMonday, May 12, 2025Conference Call Time6:00PM ETUpcoming EarningsAtossa Genetics' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Atossa Genetics Earnings HeadlinesAtossa Genetics' Endoxifen Gains Attention as Well-Tolerated Breast Cancer OptionMay 21, 2026 | americanbankingnews.comAtossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular DystrophyMay 20, 2026 | prnewswire.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 25 at 1:00 AM | Brownstone Research (Ad)Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research TranscriptMay 19, 2026 | seekingalpha.comAtossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast CancerMay 14, 2026 | prnewswire.comAtossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 8, 2026 | prnewswire.comSee More Atossa Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atossa Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atossa Genetics and other key companies, straight to your email. Email Address About Atossa GeneticsAtossa Genetics (NASDAQ:ATOS), Inc. is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies. The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence. In addition, Atossa has developed a proprietary intraductal microcatheter platform that enables direct delivery of therapeutic agents into the milk ducts, aiming to concentrate treatment at the tumor site while minimizing systemic side effects. Complementing these programs are diagnostic initiatives that utilize nipple aspirate fluid analysis to identify molecular changes associated with early-stage disease. Founded in 2009, Atossa Genetics has advanced its clinical programs through collaborations with leading academic and research institutions across North America. The company’s trials are conducted at major cancer centers and specialized breast health clinics, reflecting its commitment to rigorous scientific evaluation and patient-centric development. Under the leadership of CEO Steven C. Quay, MD, PhD, Atossa’s management team brings extensive experience in oncology drug development, regulatory affairs, and commercial strategy. The company continues to prioritize innovation in breast health by advancing its proprietary therapeutic and diagnostic platforms toward regulatory milestones and potential commercialization.View Atossa Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Earnings Beat Sends Stock To New HighsWas Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsApparel Earnings Winners and Losers: Ralph Lauren Takes OffWhy Walmart, Target and TJX Got Such Different Reactions After EarningsThe Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearOverextended, e.l.f. Beauty Is Primed to Rebound in Back Half Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
